Distinct differences in tachykinin gene expression in ulcerative colitis, Crohn's disease and diverticular disease: A role for hemokinin-1?

Neurogastroenterology and Motility

Volumn 23, Issue 5, 2011, Pages

  Liu, L ^a   Markus, I ^a   Saghire, H E ^a   Perera, D S ^b   King, D W ^b   Burcher, E ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

Author keywords

Acute diverticular disease; Crohn's disease; Human colon; Tachykinin; Ulcerative colitis

Indexed keywords

COLLAGEN FIBER; HEMOKININ 1; NEUROKININ A; SUBSTANCE P; TACHYKININ; TACHYKININ RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLON CROHN DISEASE; COLON DIVERTICULOSIS; COLON MUCOSA; ENTERITIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE MOTILITY; INTESTINE SECRETION; MALE; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; ULCERATIVE COLITIS;

ADULT; AGED; AGED, 80 AND OVER; COLITIS, ULCERATIVE; COLON; CROHN DISEASE; DIVERTICULITIS; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; PROTEIN ISOFORMS; RNA, MESSENGER; TACHYKININS; YOUNG ADULT;

EID: 79954423530     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2011.01685.x     Document Type: Article

References (43)

1. Pennefather JN, Lecci A, Candenas ML, Patak E, Pinto FM, Maggi CA. Tachykinins and tachykinin receptors: a growing family. Life Sci 2004; 74: 1445-63.
2. Page NM. New Challenges in the study of the mammalian tachykinins. Peptides 2005; 26: 1356-68.
3. Zhang Y, Lu L, Furlonger C, Wu GE, Paige CJ. Hemokinin is a hematopoietic-specific tachykinin that regulates B lymphopoiesis. Nat Immunol 2000; 1: 392-7.
4. Page NM, Bell NJ, Gardiner SM et al. Characterization of the endokinins: human tachykinins with cardiovascular activity. Proc Natl Acad Sci USA 2003; 100: 6245-50.
5. Page NM. Hemokinins and endokinins. Cell Mol Life Sci 2004; 61: 1652-63.
6. Klasserta TE, Pintob F, Hernándezax M et al. Differential expression of neurokinin B and hemokinin-1 in human immune cells. J Neuroimmunol 2008; 196: 27-34.
7. Kurtz MM, Wang R, Clements MK et al. Identification, localization and receptor characterization of novel mammalian substance P-like peptides. Gene 2002; 296: 205-12.
8. Berger A, Paige CJ. Hemokinin-1 has substance P-like function in U-251 MG astrocytoma cells: a pharmacological and functional study. J Neuroimmunol 2005; 164: 48-56.
9. Morteau O, LU B, Gerard C, Gerard NP. Hemokinin 1 is a full agonist at the substance P receptor. Nat Immunol 2001; 2: 1088.
10. Lecci A, Capraiti A, Altamura M, Maggi CA. Tachykinins and tachykinin receptors in the gut, with special reference to NK2 receptors in human. Auton Neurosci 2006; 127: 232-49.
11. Shimizu Y, Matsuyama H, Shiina T, Takewaki T, Furness JB. Tachykinins and their functions in the gastrointestinal tract. Cell Mol Life Sci 2008; 65: 295-311.
12. Holzer P, Holzer-Petche U. Tachykinins in the gut. Part II. Roles in neural excitation, secretion and inflammation. Pharamcol Ther 1997; 73: 219-63.
13. Holzer P, Holzer-Petche U. Tachykinins receptors in the gut: physiological and pathological implications. Curr Opin Pharmacol 2001; 1: 583-90.
14. Mantyh CR, Gates TS, Zimmerman RP et al. Receptor binding sites for substance P, but not substance K or neuromedin K, are expressed in high concentrations by arterioles, venules, and lymph nodules in surgical specimens obtained from patients with ulcerative colitis and Crohn disease. Proc Natl Acad Sci USA 1988; 85: 3235-9.
15. Renzi D, Pellegrini B, Tonelli F, Surrenti C, Calabro A. Substance P (neurokinin-1) and neurokinin A (neurokinin-2) receptor gene and protein expression in the healthy and inflamed human intestine. Am J Pathol 2000; 157: 1511-22.
16. Weinstock JV. The role of substance P, hemokinin and their receptor in governing mucosal inflammation and granulomatous responses. Front Biosci 2004; 9: 1936-43.
17. Goode T, O'Connell J, Anton P et al. Neurokinin-1 receptor expression in inflammatory bowel disease: molecular quantitation and localisation. Gut 2000; 47: 387-96.
18. O'Connor TM, O'Connell J, O'Brien DI, Goode T, Bredin CP, Shanahan F. The role of substance P in inflammatory disease. J Cell Physiol 2004; 201: 167-80.
19. Lee CM, Kumar RK, Lubowski DZ, Burcher E. Neuropeptides and nerve growth in inflammatory bowel diseases: a quantitative immunohistochemical study. Dig Dis Sci 2002; 47: 495-502.
20. Burcher E, Shang F, Warner F et al. Tachykinin NK2 receptor and functional mechanisms in human colon: changes with indomethacin and in diverticular disease and ulcerative colitis. J Pharmacol Exp Ther 2008; 324: 170-8.
21. Liu L, Shang F, Markus I, Burcher E. Roles of substance P receptors in human colon circular muscle: alterations in diverticular disease. J Pharmacol Exp Ther 2002; 302: 627-35.
22. Metwali A, Blum AM, Elliot DE, Setiawan T, Weinstock JV. Cutting edge: hemokinin has substance P-like function and expression in inflammation. J Immunol 2004; 172: 6528-32.
23. Glare EM, Divjak M, Bailey MJ, Walters EH. ß-Actin and GAPDH housekeeping gene expression in asthmatic airways is variable and not suitable for normalising mRNA levels. Thorax 2002; 57: 765-70.
24. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
25. Jaafari N, Khomitch-Baud A, Gilhodes JC, Hua G, Julé Y. Qualitative and quantitative analysis of tachykinin NK2 receptors in chemically defined human colonic neuronal pathways. J Comp Neurol 2008; 507: 1542-58.
26. Warner FJ, Liu L, Lubowski DZ, Burcher E. Circular muscle contraction, messenger signaling and localization of binding sites for neurokinin A in human sigmoid colon. Clin Exp Pharmacol Physiol 2000; 27: 928-33.
27. Bellucci F, Carini F, Catalani C et al. Pharmacological profile of the novel mammalian tachykinin, hemokinin 1. Br J Pharmacol 2002; 135: 266-74.
28. Jönsson M, Norrgård O, Forsgren S. Substance P and the neurokinin-1 receptor in relation to eosinophilia in ulcerative colitis. Peptides 2005; 26: 799-814.
29. Dai L, Perera DS, Burcher E, Liu L. The novel tachykinin peptide, hemokinin-1 stimulates prostaglandin E2 release in human colonic smooth muscle and mucosa. Dig Dis Week (abstract), 2009; W1693.
30. Deban L, Correale C, Vetrano S, Malesci A, Danese S. Multiple pathogenic roles of microvasculature in inflammatory bowel disease: a Jack of all trades. Am J Pathol 2008; 172: 1457-66.
31. Dueñas PI, Maté JJ, Salcedo MX, Abreu MT, Moreno OR, Gisbert JP. Analysis of soluble angiogenic factors in Crohn's disease: a preliminary study. Gastroenterol Hepatol 2007; 30: 518-24.
32. Oikonomou KA, Kapsoritakis AN, Kapsoritaki AI et al. Angiogenin, angiopoietin-1, angiopoietin-2, and endostatin serum levels in inflammatory bowel disease. Inflamm Bowel Dis 2010; doi: 10.1002/ibd.21410 [Epub ahead of print].
33. Mantyh CR, Vigna SR, Bollinger RR, Mantyh PW, Maggio JE, Pappas TN. Differential expression of substance P receptors in patients with Crohn's disease and ulcerative colitis. Gastroenterology 1995; 109: 850-60.
34. Mazumdar S, Das KM. Immunocytochemical localization of vasoactive intestinal peptide and substance P in the colon from normal subjects and patients with inflammatory bowel disease. Am J Gastroenterol 1992; 87: 176-81.
35. Bernstein CN, Robert ME, Eysselein VE. Rectal substance P concentrations are increased in ulcerative colitis but not in Crohn's disease. Am J Gastroenterol 1993; 88: 908-13.
36. Koch TR, Carney JA, Go VLW. Distribution and quantitation of gut neuropeptides in normal intestine and inflammatory bowel diseases. Dig Dis Sci 1987; 32: 369-76.
37. Menzies JR, McKee R, Corbett AD. Differential alterations in tachykinin NK2 receptors in isolated colonic circular smooth muscle in inflammatory bowel disease and idiopathic chronic constipation. Regul Pept 2001; 99: 151-6.
38. Al-Saffar A, Hellström PM. Contractile responses to natural tachykinins and selective tachykinin analogs in normal and inflamed ileal and colonic muscle. Scand J Gastroenterol 2001; 36: 485-93.
39. Cao W, Vrees MD, Kirber MT, Fiocchi C, Pricolo VE. Hydrogen peroxide contributes to motor dysfunction in ulcerative colitis. Am J Physiol Gastrointest Liver Physiol 2004; 286: G833-43.
40. Vrees MD, Pricolo VE, Potenti FM, Cao W. Abnormal motility in patients with ulcerative colitis: the role of inflammatory cytokines. Arch Surg 2002; 137: 439-45; discussion 445-436.
41. Commane DM, Arasaradnam RP, Mills S, Mathers JC, Bradburn M. Diet, ageing and genetic factors in the pathogenesis of diverticular disease. World J Gastroenterol 2009; 15: 2479-88.
42. Tursi A, Brandimarte G, Elisei W et al. Assessment and grading of mucosal inflammation in colonic diverticular disease. J Clin Gastroenterol 2008; 42: 699-703.
43. Simpson J, Sundler F, Humes DJ, Jenkins D, Scholefield JH, Spiller RC. Post inflammatory damage to the enteric nervous system in diverticular disease and its relationship to symptoms. Neurogastroenterol Motil 2009; 21: 847-e58.